Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab, Sintilimab, and Chemotherapy in First-Line Extensive-Stage Small Cell Lung Cancer
NCT07061535Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafolecimab in small cell lung cancer (SCLC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jul 2025; status: recruiting.
02
Drugs
tafolecimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07061535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061535.